These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 30329034)
21. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005 [TBL] [Abstract][Full Text] [Related]
22. Clinical features and treatment responses in pediatric lymphocytic and collagenous colitis. Narla NP; Smyrk TC; Pardi DS; Tung J J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):557-61. PubMed ID: 23820404 [TBL] [Abstract][Full Text] [Related]
23. Clinical course of microscopic colitis in a single-center cohort study. Calabrese C; Gionchetti P; Liguori G; Areni A; Fornarini GS; Campieri M; Rizzello F J Crohns Colitis; 2011 Jun; 5(3):218-21. PubMed ID: 21575884 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. Miehlke S; Aust D; Mihaly E; Armerding P; Böhm G; Bonderup O; Fernández-Bañares F; Kupcinskas J; Munck LK; Rehbehn KU; Nacak T; Greinwald R; Münch A; Gastroenterology; 2018 Dec; 155(6):1795-1804.e3. PubMed ID: 30195447 [TBL] [Abstract][Full Text] [Related]
25. Bile Acid Sequestrant Therapy in Microscopic Colitis. Northcutt MJ; Gentile NM; Goldstein JL; Yen EF J Clin Gastroenterol; 2022 Feb; 56(2):161-165. PubMed ID: 33443968 [TBL] [Abstract][Full Text] [Related]
26. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. Rindom Krogsgaard L; Kristian Munck L; Bytzer P; Wildt S Scand J Gastroenterol; 2019 Apr; 54(4):446-452. PubMed ID: 31009268 [No Abstract] [Full Text] [Related]
27. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Mosli MH; MacDonald JK; Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; Khanna R; Feagan BG Inflamm Bowel Dis; 2015 May; 21(5):1151-9. PubMed ID: 25844963 [TBL] [Abstract][Full Text] [Related]
35. Smoking Status Influences Clinical Outcome in Collagenous Colitis. Münch A; Tysk C; Bohr J; Madisch A; Bonderup OK; Mohrbacher R; Mueller R; Greinwald R; Ström M; Miehlke S J Crohns Colitis; 2016 Apr; 10(4):449-54. PubMed ID: 26721941 [TBL] [Abstract][Full Text] [Related]
36. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Boden EK; Shows DM; Chiorean MV; Lord JD Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476 [TBL] [Abstract][Full Text] [Related]
37. [Locally acting corticosteroids in microscopic colitis: are they the treatment of choice? How should they be used?]. Marín-Jiménez I; Yepes Barreto I Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():22-6. PubMed ID: 19087860 [No Abstract] [Full Text] [Related]
40. Efficacy of budesonide in collagenous colitis Evaluation of: Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146(5):1222-1230 e1222. Drug VL; Antoniu SA Expert Opin Pharmacother; 2014 Oct; 15(15):2277-9. PubMed ID: 25164577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]